{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+Emission+Tomography+%28PET%29+Imaging&page=32",
    "query": {
      "intervention": "Positron Emission Tomography (PET) Imaging",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 1851,
    "total_pages": 186,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+Emission+Tomography+%28PET%29+Imaging&page=33&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+Emission+Tomography+%28PET%29+Imaging&page=31&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T22:53:45.618Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07609225",
      "title": "Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "3'-Deoxy-3'-[18F]-fluorothymidine",
          "type": "DRUG"
        },
        {
          "name": "Chemical-shift-encoded MRI",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2026-10",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-16T22:53:45.618Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07609225"
    },
    {
      "nct_id": "NCT00605254",
      "title": "PET Imaging of P-glycoprotein Function Using [11C]dLop",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "51 Years",
        "sex": "ALL",
        "summary": "18 Years to 51 Years"
      },
      "enrollment_count": 58,
      "start_date": "2008-01-24",
      "completion_date": "2014-09-04",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-10-16T22:53:45.618Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00605254"
    },
    {
      "nct_id": "NCT03930173",
      "title": "18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Secondary Malignant Neoplasm of Brain and Cerebral Meninges"
      ],
      "interventions": [
        {
          "name": "18F-fluciclovine",
          "type": "DRUG"
        },
        {
          "name": "PET/CT of the brain",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2019-07-02",
      "completion_date": "2021-03-01",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-10-16T22:53:45.618Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03930173"
    },
    {
      "nct_id": "NCT01788280",
      "title": "Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme (GBM)"
      ],
      "interventions": [
        {
          "name": "Fluciclitite , PET imaging, and Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-01",
      "completion_date": "2022-01",
      "has_results": false,
      "last_update_posted_date": "2018-02-07",
      "last_synced_at": "2026-10-16T22:53:45.618Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01788280"
    },
    {
      "nct_id": "NCT01459237",
      "title": "Effects of Hormone Stimulation on Brain Scans for Cushing s Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Pituitary Neoplasm"
      ],
      "interventions": [
        {
          "name": "Acthrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2011-10-11",
      "completion_date": "2018-06-12",
      "has_results": false,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-10-16T22:53:45.618Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01459237"
    },
    {
      "nct_id": "NCT06470282",
      "title": "Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Muscle-Invasive Bladder Carcinoma",
        "Stage II Bladder Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intensity Modulated Radiation Therapy (IMRT)",
          "type": "RADIATION"
        },
        {
          "name": "Transurethral Resection of Bladder Tumor",
          "type": "PROCEDURE"
        },
        {
          "name": "Cystoscopy (CS)",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography (CT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging (MRI)",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography (PET)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2025-03-31",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-16T22:53:45.618Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06470282"
    },
    {
      "nct_id": "NCT05957159",
      "title": "Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "Detoxification Program",
          "type": "OTHER"
        },
        {
          "name": "PKAB",
          "type": "RADIATION"
        },
        {
          "name": "CFN",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 100,
      "start_date": "2023-11-07",
      "completion_date": "2028-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-16T22:53:45.618Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05957159"
    },
    {
      "nct_id": "NCT03907488",
      "title": "Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ann Arbor Stage III Hodgkin Lymphoma",
        "Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma",
        "Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma",
        "Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma",
        "Ann Arbor Stage IV Hodgkin Lymphoma",
        "Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma",
        "Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma",
        "Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma",
        "Classic Hodgkin Lymphoma",
        "Lymphocyte-Rich Classic Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Vinblastine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 994,
      "start_date": "2019-08-29",
      "completion_date": "2027-03-28",
      "has_results": true,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-16T22:53:45.618Z",
      "location_count": 711,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 472 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03907488"
    },
    {
      "nct_id": "NCT06503146",
      "title": "18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma",
        "Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)",
        "Mesothelioma",
        "Pheochromocytoma/Paraganglioma (PPGL)",
        "Pancreatic Ductal Adenocarcinoma",
        "Ovarian Cancer",
        "Hepatocellular Carcinoma",
        "Gastric Cancer",
        "Cholangiocarcinoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "[18F]FAPI-74",
          "type": "DRUG"
        },
        {
          "name": "[18F]FDG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 320,
      "start_date": "2025-09-09",
      "completion_date": "2030-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-10-16T22:53:45.618Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06503146"
    },
    {
      "nct_id": "NCT05242744",
      "title": "FTT PET/CT in Metastatic Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "[18F]FluorThanatrace",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2023-03-01",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-16T22:53:45.618Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05242744"
    }
  ]
}